AxoGen, Inc. (NASDAQ:AXGN – Get Free Report) was the target of a significant decline in short interest in July. As of July 31st, there was short interest totalling 1,960,000 shares, a decline of 19.7% from the July 15th total of 2,440,000 shares. Based on an average trading volume of 387,700 shares, the short-interest ratio is currently 5.1 days.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on AXGN shares. Raymond James started coverage on AxoGen in a research report on Monday, July 1st. They issued an “outperform” rating and a $13.00 target price on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 target price on shares of AxoGen in a research report on Thursday, June 20th. StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a research report on Friday, August 9th. Finally, JMP Securities upped their price objective on AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a research report on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $13.80.
Get Our Latest Stock Analysis on AXGN
Institutional Inflows and Outflows
AxoGen Trading Up 6.4 %
Shares of AXGN traded up $0.71 during mid-day trading on Friday, reaching $11.73. 430,712 shares of the company’s stock traded hands, compared to its average volume of 400,561. The stock has a market cap of $512.66 million, a P/E ratio of -23.46 and a beta of 1.11. The stock’s 50-day moving average is $8.46 and its two-hundred day moving average is $8.08. AxoGen has a 12 month low of $3.45 and a 12 month high of $11.76. The company has a debt-to-equity ratio of 0.72, a current ratio of 3.43 and a quick ratio of 2.23.
About AxoGen
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Featured Articles
- Five stocks we like better than AxoGen
- How to Find Undervalued Stocks
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How to Invest in the Best Canadian Stocks
- MarketBeat Week in Review – 8/12 – 8/16
- How to Invest in Biotech Stocks
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.